1. Home
  2. MXCT vs IDE Comparison

MXCT vs IDE Comparison

Compare MXCT & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

SELL

Current Price

$1.38

Market Cap

155.8M

Sector

Health Care

ML Signal

SELL

Logo Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

IDE

Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

SELL

Current Price

$10.82

Market Cap

179.6M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
MXCT
IDE
Founded
1999
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
155.8M
179.6M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
MXCT
IDE
Price
$1.38
$10.82
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
★ $4.11
N/A
AVG Volume (30 Days)
★ 1.4M
47.0K
Earning Date
11-10-2026
01-01-0001
Dividend Yield
N/A
★ 8.83%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $33,026,000.00
N/A
Revenue This Year
$4.77
N/A
Revenue Next Year
$10.06
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.64
$11.14
52 Week High
$1.80
$14.30

Technical Indicators

Market Signals
Indicator
MXCT
IDE
Relative Strength Index (RSI) 55.07 27.17
Support Level $1.02 N/A
Resistance Level $1.54 $13.95
Average True Range (ATR) 0.14 0.32
MACD -0.01 -0.08
Stochastic Oscillator 70.41 0.00

Price Performance

Historical Comparison
MXCT
IDE

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

Share on Social Networks: